Urease-powered nanobots for radionuclide bladder cancer therapy
Simó, Cristina (Basque Research & Technology Alliance)
Serra-Casablancas, Meritxell (Institut de Bioenginyeria de Catalunya)
Hortelão, A. C. L. (Institut de Bioenginyeria de Catalunya)
Di Carlo, Valerio (Institut de Bioenginyeria de Catalunya)
Guallar Garrido, Sandra (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia)
Plaza-García, Sandra (Basque Research & Technology Alliance)
Rabanal Prados, Rosa Ma (Universitat Autònoma de Barcelona. Departament de Medicina i Cirurgia Animals)
Ramos-Cabrer, Pedro (Basque Research & Technology Alliance)
Yagüe, Balbino (Basque Research & Technology Alliance)
Aguado, Laura (Basque Research & Technology Alliance)
Bardia, Lídia (Institut de Recerca Biomèdica)
Tosi, Sébastien (Institut de Recerca Biomèdica)
Gómez Vallejo, Vanessa (Basque Research & Technology Alliance)
Martín, Abraham (IKERBASQUE)
Patiño, Tania (Institut de Bioenginyeria de Catalunya)
Julián Gómez, Esther (Universitat Autònoma de Barcelona. Departament de Genètica i de Microbiologia)
Colombelli, Julien (Institut de Recerca Biomèdica)
Llop, Jordi (Basque Research & Technology Alliance)
Sánchez, Samuel (Institut de Bioenginyeria de Catalunya)

Date:	2024
Abstract:	Bladder cancer treatment via intravesical drug administration achieves reasonable survival rates but suffers from low therapeutic efficacy. To address the latter, self-propelled nanoparticles or nanobots have been proposed, taking advantage of their enhanced diffusion and mixing capabilities in urine when compared with conventional drugs or passive nanoparticles. However, the translational capabilities of nanobots in treating bladder cancer are underexplored. Here, we tested radiolabelled mesoporous silica-based urease-powered nanobots in an orthotopic mouse model of bladder cancer. In vivo and ex vivo results demonstrated enhanced nanobot accumulation at the tumour site, with an eightfold increase revealed by positron emission tomography in vivo. Label-free optical contrast based on polarization-dependent scattered light-sheet microscopy of cleared bladders confirmed tumour penetration by nanobots ex vivo. Treating tumour-bearing mice with intravesically administered radio-iodinated nanobots for radionuclide therapy resulted in a tumour size reduction of about 90%, positioning nanobots as efficient delivery nanosystems for bladder cancer therapy. Bladder cancer treatment suffers from low therapeutic efficacy. Here the authors present radioactive 131 I-labelled urease-powered nanobots that exhibit enhanced accumulation at the tumour site, enabling effective radionuclide therapy at low doses as an alternative treatment option for bladder cancer.
Grants:	European Commission 866348 Agencia Estatal de Investigación PID2021-122331OB-I00 Agencia Estatal de Investigación PID2020-117656RB-I00 Agencia Estatal de Investigación CEX2018-000789 Agència de Gestió d'Ajuts Universitaris i de Recerca 2021/SGR-01606 Agència de Gestió d'Ajuts Universitaris i de Recerca 2021/SGR-0092 "la Caixa" Foundation LCF/PR/HR21/52410022
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Nanotechnology in cancer ; Imaging techniques and agents ; Nanoparticles
Published in:	Nature Nanotechnology, Vol. 19, no. 4 (April 2024) , p. 554-564, ISSN 1748-3395

DOI: 10.1038/s41565-023-01577-y
PMID: 38225356

19 p, 3.1 MB

The record appears in these collections:
Articles > Research articles
Articles > Published articles